Aptose Biosciences (NASDAQ:APTO) Stock Price Passes Above Fifty Day Moving Average – Here’s Why

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS)’s stock price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.38 and traded as high as $0.40. Aptose Biosciences shares last traded at $0.40, with a volume of 56,531 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on Aptose Biosciences in a research note on Wednesday. They issued a “hold” rating on the stock.

Aptose Biosciences Trading Up 4.9 %

The company has a 50 day moving average price of $0.38 and a 200-day moving average price of $0.65. The company has a market cap of $7.23 million, a P/E ratio of -0.09 and a beta of 1.26.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.